BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. (BMRN) entered into a material definitive agreement (8-K Item 1.01) filed on 2026-09-30. The excerpt contains only the filing cover page; the full terms of the agreement are in the attached exhibit. Material definitive agreements are binding corporate commitments that can alter strategy, capital structure, or partnerships in ways that matter for equity holders.

Robert M. Plenge, newly appointed as Director of BioMarin Pharmaceutical (BMRN) effective September 10, 2026, filed a Form 3 reporting no securities beneficially owned at the date of filing. His separately announced RSU grant valued at $400,000 will be reported in a subsequent Form 4 or was not yet issued at the date of the event requiring this statement. This is a required initial ownership disclosure for new insiders — purely administrative.

BioMarin Pharmaceutical (BMRN) expanded its Board from 10 to 11 members by appointing Robert Plenge, M.D., Ph.D., effective September 10, 2026, also adding him to the Science and Technology Committee. Dr. Plenge will receive standard non-employee director fees plus a pro-rated RSU grant valued at $400,000 vesting prior to the next annual meeting, under the company's 2017 Equity Incentive Plan. He was not appointed pursuant to any third-party arrangement, and a standard indemnification agreement will be executed. This is a routine director appointment adding scientific expertise to the board — minimal financial impact.

BioMarin Pharmaceutical Inc. entered into a binding term sheet with Ascendis Pharma on August 30, 2026, settling all pending patent litigation and granting Ascendis a non-exclusive, worldwide, royalty-bearing license to commercialize navepegritide (TransCon CNP / Yuviwel) for achondroplasia, hypochondroplasia, and other indications. Ascendis will pay royalties of 20% of U.S. net sales and 18% of EU/Brazil/South Korea net sales, applied retroactively from first commercial sale until May 2030. The settlement adds a material royalty revenue stream for BioMarin while removing litigation risk and clearing Ascendis's commercial path — material and accretive for BioMarin.

BioMarin Pharmaceutical agreed to acquire Alesta Therapeutics B.V. (a Dutch private rare disease company developing oral small molecule therapies) via a share purchase for $275 million upfront (cash-free, debt-free basis, subject to post-closing price adjustment) plus up to $215 million in contingent development milestone payments, totaling up to $490 million. The deal includes a pre-closing transfer of certain Alesta assets to a separate SpinCo entity; closing is expected in Q3 2026 subject to customary conditions. This is a strategic bolt-on that expands BioMarin's rare disease pipeline, with substantial milestone contingencies adding deal-value uncertainty.